Search
Choice data reveals that this year, 14 biomedical and medical device enterprises have successfully debuted on the Hong Kong Stock Exchange, with another 36 related enterprises eagerly awaiting their turn. The pharmaceutical sector has emerged as a prominent player in Hong Kong's stock market, and this momentum shows no signs of waning as we move into the second half of the year. Multiple interviewees highlighted that the current crop of popular pharmaceutical enterprises boasts not only robust R&D pipelines but also substantial clinical data support. The Hong Kong Stock Exchange's "Science and Technology Enterprise Express Lane" and Chapter 18A listing system have fortified the path for cutting-edge biomedical enterprises to secure capital market backing, solidifying Hong Kong's position as Asia's biotechnology financing hub.
-
C114 Communication Network -
Communication Home
